Leerink Swann began coverage on shares of Adamas Pharmaceuticals (NASDAQ:ADMS) in a research note issued to investors on Wednesday, MarketBeat reports. The firm issued an outperform rating and a $31.00 price target on the specialty pharmaceutical company’s stock. Leerink Swann also issued estimates for Adamas Pharmaceuticals’ Q1 2018 earnings at ($1.41) EPS, Q2 2018 earnings at ($1.50) EPS, Q3 2018 earnings at ($1.47) EPS, Q4 2018 earnings at ($1.47) EPS, FY2018 earnings at ($5.81) EPS, FY2019 earnings at ($4.77) EPS, FY2020 earnings at ($1.75) EPS, FY2021 earnings at $1.27 EPS and FY2022 earnings at $4.03 EPS.
Other equities analysts have also recently issued reports about the company. ValuEngine upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a report on Friday, February 2nd. Cowen set a $55.00 price target on Adamas Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, December 13th. BidaskClub upgraded Adamas Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, January 25th. Needham & Company LLC set a $40.00 price target on Adamas Pharmaceuticals and gave the stock a buy rating in a report on Sunday, February 25th. Finally, Zacks Investment Research cut Adamas Pharmaceuticals from a hold rating to a sell rating in a report on Friday, February 23rd. Two research analysts have rated the stock with a sell rating and twelve have given a buy rating to the stock. The company has an average rating of Buy and an average price target of $42.89.
Shares of NASDAQ:ADMS opened at $22.94 on Wednesday. The company has a current ratio of 10.79, a quick ratio of 10.69 and a debt-to-equity ratio of 1.55. Adamas Pharmaceuticals has a 52-week low of $13.50 and a 52-week high of $44.00.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.84 million. The company’s revenue for the quarter was up 1435.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.68) EPS. research analysts predict that Adamas Pharmaceuticals will post -5.87 EPS for the current year.
In related news, CEO Gregory T. Went sold 4,541 shares of the stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $25.75, for a total transaction of $116,930.75. Following the transaction, the chief executive officer now owns 182,610 shares of the company’s stock, valued at approximately $4,702,207.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Rajiv Patni sold 1,252 shares of the stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $25.94, for a total value of $32,476.88. Following the transaction, the insider now directly owns 21,515 shares in the company, valued at approximately $558,099.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,360 shares of company stock worth $164,138. 29.00% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MetLife Investment Advisors LLC acquired a new position in Adamas Pharmaceuticals during the 4th quarter worth about $239,000. Macquarie Group Ltd. lifted its stake in Adamas Pharmaceuticals by 18.6% during the 4th quarter. Macquarie Group Ltd. now owns 890,962 shares of the specialty pharmaceutical company’s stock worth $30,195,000 after acquiring an additional 139,934 shares in the last quarter. Bainco International Investors acquired a new position in Adamas Pharmaceuticals during the 4th quarter worth about $681,000. Ardsley Advisory Partners acquired a new position in Adamas Pharmaceuticals during the 4th quarter worth about $5,253,000. Finally, Two Sigma Advisers LP acquired a new position in Adamas Pharmaceuticals during the 4th quarter worth about $596,000. 77.25% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/adamas-pharmaceuticals-adms-earns-outperform-rating-from-analysts-at-leerink-swann.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.